How should health technology assessment of ATMPs evolve in Europe?

Cell & Gene Therapy Insights 2020; 6(7), 1095–1101


Published: 2 September 2020
Mondher Toumi

Mondher Toumi is  MD by training, has an MSc in Biostatistics, and in Biological Sciences (option pharmacology) and a PhD in Economic Sciences. He is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995, he embraced a carrier in the pharmaceutical industry for 13 years. Dr Toumi was appointed Global Vice President at Lundbeck A/S. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. He launched the first European University Diploma of Market Access (EMAUD), an international course already followed by about more than 500 students. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP). In September 2014, he joined the research unit EA3279 of the public health department, at Aix-Marseille University (France), where he is a full Professor. Dr Toumi is also a visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books. He authored the reference book on Market Access.